EU panel backs AstraZeneca hypertension drug baxdrostat
EU panel backs AstraZeneca hypertension drug baxdrostat Nov 13 (Reuters) - AstraZeneca AZN.L said on Friday a European medicines committee had backed its hypertension pill baxdrostat, branded as Baxfendy, for marketing authorisation, potentially making it the first drug of its class to reach patients in the European Union.
The Committee for Medicinal Products for Human Use, or CHMP, recommended baxdrostat for adults whose hypertension is insufficiently controlled by at least two medicines
If approved, Baxfendy would be the EU's first and only aldosterone synthase inhibitor, AstraZeneca said. The drug works by blocking the hormone aldosterone, a different approach from older blood pressure treatments
The CHMP said its recommendation was based on positive results from two late-stage trials
Baxdrostat is already approved in the US and other countries, while filings are under review in Japan and China
AstraZeneca acquired baxdrostat as part of its $1.8 billion purchase of CinCor Pharma in 2023
While final approvals are up to the European Commission, it typically follows the CHMP's recommendation
(Reporting by Ankita Bora in Bengaluru; Editing by Tasim Zahid)
((Ankita.Bora@thomsonreuters.com))
Recent news on AstraZeneca
See all newsAstraZeneca fends off lawsuit over alleged Soliris drug monopoly (updated)
AstraZeneca fends off lawsuit over alleged Soliris drug monopoly
Sofinnova closes €725 million fund to back European biotech expansion
AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy
UK Stocks-Factors to watch on November 16 (updated)